Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Trospium

No authors listed
In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
.
Free Books & Documents
Review

Trospium

No authors listed.
Free Books & Documents

Excerpt

Trospium is an antispasmotic and anticholinergic agent used to treat urinary incontinence and overactive bladder syndrome. Trospium has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.

PubMed Disclaimer

References

    1. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.(Expert review of hepatotoxicity published in 1999 before the availability of trospium and other therapies of overactive bladder syndrome).
    1. Brown JH, Brandl K, Wess J. Therapeutic uses of muscarinic receptor antagonists: Muscarinic receptor agonists and antagonists. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 156-9.(Textbook of pharmacology and therapeutics).
    1. Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M, Lehmacher W, Strösser W, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. 2000;85:659-64.(Among 208 adults with “detrusor instability” treated with trospium [20 mg] or placebo twice daily for 3 weeks, bladder capacity increased with trospium but not with placebo, while adverse event rates were similar in the two groups [68% vs 62%]; no mention of ALT elevations or hepatotoxicity). - PubMed
    1. Singh-Franco D, Machado C, Tuteja S, Zapantis A. Trospium chloride for the treatment of overactive bladder with urge incontinence. Clin Ther 2005; 27: 511-30.(Systematic review of efficacy and safety of trospium found major side effects to be dry mouth, constipation, and gastrointestinal upset; rare, post-marketing adverse events included Stevens Johnson syndrome, but no mention of hepatotoxicity or ALT elevations). - PubMed
    1. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67:275-80.(Among 658 adults with symptomatic overactive bladder syndrome treated with trospium [20 mg] or placebo twice daily for 12 weeks, numbers of micturition, urgency and incontinence episodes were slightly less with trospium beginning at week 1, while adverse event rates were higher for dry mouth and constipation; no mention of ALT elevations but “no clinically meaningful differences were found between the treatment groups in clinical laboratory data”). - PubMed

LinkOut - more resources